Literature DB >> 11917091

Function and genetics of dystrophin and dystrophin-related proteins in muscle.

Derek J Blake1, Andrew Weir, Sarah E Newey, Kay E Davies.   

Abstract

The X-linked muscle-wasting disease Duchenne muscular dystrophy is caused by mutations in the gene encoding dystrophin. There is currently no effective treatment for the disease; however, the complex molecular pathology of this disorder is now being unravelled. Dystrophin is located at the muscle sarcolemma in a membrane-spanning protein complex that connects the cytoskeleton to the basal lamina. Mutations in many components of the dystrophin protein complex cause other forms of autosomally inherited muscular dystrophy, indicating the importance of this complex in normal muscle function. Although the precise function of dystrophin is unknown, the lack of protein causes membrane destabilization and the activation of multiple pathophysiological processes, many of which converge on alterations in intracellular calcium handling. Dystrophin is also the prototype of a family of dystrophin-related proteins, many of which are found in muscle. This family includes utrophin and alpha-dystrobrevin, which are involved in the maintenance of the neuromuscular junction architecture and in muscle homeostasis. New insights into the pathophysiology of dystrophic muscle, the identification of compensating proteins, and the discovery of new binding partners are paving the way for novel therapeutic strategies to treat this fatal muscle disease. This review discusses the role of the dystrophin complex and protein family in muscle and describes the physiological processes that are affected in Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917091     DOI: 10.1152/physrev.00028.2001

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  377 in total

1.  The interaction with HMG20a/b proteins suggests a potential role for beta-dystrobrevin in neuronal differentiation.

Authors:  Benedetta Artegiani; Catherine Labbaye; Antonella Sferra; Maria Teresa Quaranta; Paola Torreri; Gianfranco Macchia; Marina Ceccarini; Tamara C Petrucci; Pompeo Macioce
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  Patterning, prestress, and peeling dynamics of myocytes.

Authors:  Maureen A Griffin; Adam J Engler; Thomas A Barber; Kevin E Healy; H Lee Sweeney; Dennis E Discher
Journal:  Biophys J       Date:  2004-02       Impact factor: 4.033

Review 3.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

4.  β1D chain increases α7β1 integrin and laminin and protects against sarcolemmal damage in mdx mice.

Authors:  Jianming Liu; Derek J Milner; Marni D Boppart; Robert S Ross; Stephen J Kaufman
Journal:  Hum Mol Genet       Date:  2011-12-16       Impact factor: 6.150

5.  Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design.

Authors:  Ava Yun Lin; Ewa Prochniewicz; Davin M Henderson; Bin Li; James M Ervasti; David D Thomas
Journal:  J Mol Biol       Date:  2012-04-11       Impact factor: 5.469

6.  Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Authors:  Jung Hae Yoon; Eric Johnson; Rui Xu; Laura T Martin; Paul T Martin; Federica Montanaro
Journal:  J Proteome Res       Date:  2012-07-30       Impact factor: 4.466

7.  Alpha 7 integrin preserves the function of the extensor digitorum longus muscle in dystrophin-null mice.

Authors:  Chady H Hakim; Dean J Burkin; Dongsheng Duan
Journal:  J Appl Physiol (1985)       Date:  2013-08-29

Review 8.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

9.  Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy.

Authors:  Laurin M Hanft; Daniel J Bogan; Ulrike Mayer; Stephen J Kaufman; Joe N Kornegay; James M Ervasti
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

10.  Rational design of antisense oligomers to induce dystrophin exon skipping.

Authors:  Chalermchai Mitrpant; Abbie M Adams; Penny L Meloni; Francesco Muntoni; Sue Fletcher; Steve D Wilton
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.